European biotech flourishes as US and Asian capital pours in
Despite benefiting from five times less investment compared with the US, the European biotech sector has blossomed in recent years, attracting increasing financing from a diversified mix of investors and producing several healthcare unicorns. Alessia Argentieri reports
More on Investments
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Evoco expects portfolio acquisitions, assesses potential exits in 2H23
Switzerland-headquartered GP is currently deploying equity via its EUR 162m Evoco TSE III fund
Turning the tables – an M&A downturn means investment banks are now targets themselves
Some dealmakers with healthy balance sheets and willingness to go countercyclical are pursing acquisitions
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds